Data from Pivotal FIREFISH and SUNFISH Studies Demonstrate Clinical Benefit of Risdiplam in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

Tuesday, May 7, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Babies with Type 1 SMA from Part 1 of FIREFISH continue to achieve motor milestones including standing

SUNFISH

MFM32

Aged 2-11(n=24)

Aged 12-25(n=19)

Aged 2-25(n=43)*

Total MFM change from baseline, mean (SD)

3.47 (3.77)

1.64 (3.43)

2.66 (3.70)

Total MFM change from baseline, median (range)

4.17 (-6.3, -9.4)

2.08 (-7.3, -6.3)

3.13 (-7.3, -9.4)

Proportion of patients who achieveimprovement (i.e. a change frombaseline in MFM score ?3), % (n)

70.8 (17/24)

42.1 (8/19)

58.1 (25/43)

*Excludes 7 patients who performed the MFM20 assessment (only patients who performed the full MFM32 assessment are included in the analysis) and one patient who had dropped out of the study prior to the Month 12 visit.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store